Octreotide for acromegaly treatment: a reappraisal.
Title | Octreotide for acromegaly treatment: a reappraisal. |
Publication Type | Journal Article |
Year of Publication | 2013 |
Authors | Giustina, A., Karamouzis I., Patelli I., & Mazziotti G. |
Journal | Expert Opin Pharmacother |
Volume | 14 |
Issue | 17 |
Pagination | 2433-47 |
Date Published | 2013 Dec |
ISSN | 1744-7666 |
Keywords | Acromegaly, Antineoplastic Agents, Hormonal, Humans, Neoplasms, Octreotide |
Abstract | INTRODUCTION: Acromegaly is a rare disorder characterized by excess secretion of growth hormone (GH) generally caused by a pituitary macroadenoma and associated with reduced life expectancy if the disease is untreated. This article covers the recent available evidences published on octreotide , the first somatostatin analog introduced into clinical practice for the medical treatment of acromegaly.AREAS COVERED: This article discusses i) pharmacology of somatostatin and octreotide; ii) biochemical effects of regular octreotide and long-acting repeatable formulation; iii) tumor shrinkage effects of octreotide in acromegaly; iv) impact of octreotide on acromegalic clinical manifestations and chronic complications; v) safety of octreotide and vi) place of octreotide in the guidelines for acromegaly treatment. Full-text articles in the English language were selected from a PubMed search spanning 1984 - 2013, for keywords including 'octreotide,' 'acromegaly,' 'GH,' 'IGF-I,' and 'tumor shrinkage.' Reference lists in selected papers were also used to broaden the search.EXPERT OPINION: Octreotide is a mature drug with a consolidated favorable benefit versus risks profile in the treatment of acromegaly. |
DOI | 10.1517/14656566.2013.847090 |
Alternate Journal | Expert Opin Pharmacother |
PubMed ID | 24124691 |